Can Sanofi’s CirCLIQ strategy change how anti-CD38 therapies reach patients?
Discover how wearable injectors could reshape multiple myeloma treatment, clinic capacity and the competitive battle between Sarclisa and daratumumab.
Features & Analysis
Pharma & Biotech
Could Sanofi’s Sarclisa SC approval change how Japan treats multiple myeloma?
Find out how Sanofi’s Sarclisa SC approval in Japan could change multiple myeloma treatment delivery and strengthen its oncology strategy today!